CAR-T makers asked by FDA to add boxed warnings of secondary cancer

The FDA has called on Novartis, Gilead, Bristol Myers Squibb and Johnson & Johnson to add boxed warnings on the labels of six CAR-T therapies noting the risks of secondary cancer.

The agency caused a stir in the CAR-T space when it revealed the safety review in…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks